Improved Fermentation Processes for NS0 Cell Lines Expressing Human Antibodies and Glutamine Synthetase

To meet the increasing requirement for therapeutic antibodies to conduct clinical trials, an enhanced culture medium and fed‐batch process was developed for GS‐NS0 cell lines. This process was shown to produce high concentrations of monoclonal antibodies for several cell lines expressing different antibodies. Cells were adapted to growth in a glutamine‐ and serum‐free medium containing bovine serum albumin (BSA), cholesterol, and transferrin. A number of amino acids were found to be depleted during cell culture. The concentrations of these amino acids were increased, and further cell culture analyses were performed. This process of cell growth and analysis was repeated over multiple cycles until no depletion was detected. This resulted in an amino acid supplement that was shown to be generic and enhanced antibody productivity up to 5‐fold for the three cell lines tested. Transferrin was replaced using tropolone, a lipophilic iron chelator and ferric ammonium citrate. Cell growth was equivalent to that in transferrin‐containing medium over the wide ranges tested. A concentrated feed solution, based on the amino acid supplement and the components of the serum‐and protein‐free supplements, was formulated. Addition of this feed in response to metabolic requirements resulted in a harvest titer a further 2‐fold higher than the enhanced culture medium. Harvest antibody titers of up to 600 mg/L were achieved for three cell lines expressing different antibodies, representing an increase of 10‐fold over the starting concentrations.

[1]  H. Blanch,et al.  Transient responses of hybridoma cells in continuous culture to step changes in amino acid and vitamin concentrations , 1994, Biotechnology and bioengineering.

[2]  S. Gillies,et al.  Expression of Human Anti-Tetanus Toxoid Antibody in Transfected Murine Myeloma Cells , 1989, Bio/Technology.

[3]  Weichang Zhou,et al.  High viable cell concentration fed‐batch cultures of hybridoma cells through on‐line nutrient feeding , 1995, Biotechnology and bioengineering.

[4]  J. Osbourn,et al.  Human antibodies by design , 1998, Nature Biotechnology.

[5]  J. Lehmann,et al.  Serum-free growth medium for the cultivation of a wide spectrum of mammalian cells in stirred bioreactors , 1988, Cytotechnology.

[6]  W M Miller,et al.  Phosphate feeding improves high-cell-concentration NS0 myeloma culture performance for monoclonal antibody production. , 2000, Biotechnology and bioengineering.

[7]  W S Hu,et al.  Kinetic study of hybridoma cell growth in continuous culture: II. Behavior of producers and comparison to nonproducers , 1991, Biotechnology and bioengineering.

[8]  F. Oliveri,et al.  Myeloma based expression system for production of large mammalian proteins. , 1991, Trends in biotechnology.

[9]  M. Lao,et al.  Development of a serum-free medium using computer-assisted factorial design and analysis , 2004, Cytotechnology.

[10]  R. Field,et al.  THE USE OF 2-HYDROXY-2,4,6-CYCLOHEPTARIN-l-ONE (TROPOLONE) AS A REPLACEMENT FOR TRANSFERRIN , 1994 .

[11]  D. King,et al.  High-Level Expression of a Recombinant Antibody from Myeloma Cells Using a Glutamine Synthetase Gene as an Amplifiable Selectable Marker , 1992, Bio/Technology.